שווי כולל של החברה: Enveric Corp (ENVB)

Enveric Biosciences (ENVB) operates a business that is insulated from GDP fluctuations and seasonal volatility, relying on existing capital to ensure stability. The price history on the enterprise value chart is recorded at -1.94. Enveric Biosciences (ENVB) utilizes AI to synthesize non-hallucinogenic antidepressants, which streamlines their implementation. The project is currently in the preclinical stage; consequently, there is no scaling, and costs are limited to research and development.

Enterprise Value (EV) represents the total buyout price of a business, combining market capitalization and net debt to eliminate distortions caused by financing structures. By analyzing the company's market price inclusive of debt, an investor gains a real-time assessment of Enveric Biosciences (ENVB) during its psychedelic drug development phase, allowing for an evaluation of the asset's resilience during preclinical trials and strategic pivots.